ClinicalTrials.gg
Status unknownNCT03344705Updated Nov 17, 2017

Safety and Efficacy Evaluation of IM19 Cells

A Phase 1 interventional study of IM19 CAR-T and Fludarabine in Hematological Malignancies, sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd.. Status unknown at 1 site in China. Open to participants aged 4 Years to 75 Years. Per ClinicalTrials.gov, last updated 2017-11-17.

Sponsored by Beijing Immunochina Medical Science & Technology Co., Ltd. (part of Imunopharm Technology Co., Ltd.) · Phase 1, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Nov 2017), so the status shown — last known as Recruiting — may be out of date.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
20
Allocation
Not applicable
Ages
4 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-18

Among 149 studies in Hematologic Neoplasms with a site in China — 76 open to participants now, 84 under way, 8 of them phase 3. Hematologic Neoplasms · China.

Planned enrollment
97th of 123
20 · median 56
Started
2017
with 3 others
Phase 1
57 of 149
30 open now
Registered
14th of 149
by date

Among the 149 studies in Hematologic Neoplasms with a site in China, this one is the 97th largest by planned enrollment of the 123 interventional ones that give a count, is one of 4 that started in 2017, is one of 57 in phase 1, and was the 14th registered.

Hematologic Neoplasms

1,445 studies on the registry are indexed under Hematologic Neoplasms; 424 are open to participants now.

Browse Hematologic Neoplasms studies →

Open to participants now

76 of the 149 studies in Hematologic Neoplasms with a site in China are open now. Recruiting first, the newest first:

71 more — sign in →

All 76 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 315 Hematologic Neoplasms studies recruiting now, 211 (67%) set no upper age limit and 78 (25%) stop at 75 or younger; 81 take children under 18; 34 take healthy volunteers.

This study: 4 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 149 studies in Hematologic Neoplasms with a site in China, or all of them as a file.
02

Study summary

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies.

Read the detailed description

Assessment of the Safety and Feasibility of Administering T cells Expressing an Anti-CD19 Chimeric Antigen Receptor to Patients With CD19+ B-cell Hematological Malignancies(including B-cell Acute lymphoblastic Leukemia、B-cell Chronic Lymphocytic Leukemia、Non-Hodgkin's lymphoma) and Determine the Best Dosage.

03

Conditions studied

  • Hematological Malignancies
04

Who can participate

Ages eligible
4 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients with CD19 positive B-cell , including B-cell Acute Lymphocytic Leukemia(ALL)、B-cell Chronic Lymphocytic Leukemia(CLL)、Non-Hodgkin's lymphoma(NHL).

1)Patients with ALL:

  • Previously treated with at least two courses of chemotherapy Ⅱ The interval of the last chemotherapy and disease progression is less than one year.

    Ⅲ Not suitable for stem cell transplantation. 2)Patients with CLL:

  • Previously treated with at least two courses of chemotherapy

    Ⅱ The interval of the last chemotherapy and disease progression is less than two years.

    Ⅲ Not suitable for allogeneic stem cell transplantation conditions or due to conditions to abandon allogeneic stem cell transplantation.

    1. Patients with DLBCL or FL、PMBCL:
  • Patients who relapsed or were refractory after at least two previous treatments.

    Ⅱ Patients who relapsed after transplantation. 4)Patients who have relapsed or have refractory mantle cell lymphoma after at least one treatment.

    2.,including minimal residual disease. 3.Gender is not limited, to be aged 4 to 75 years 4.Expected survival >3 months. 5.(ECOG) score 0-2. 6.Women of must have a blood pregnancy test taken and proven negative prior to the treatment. All patients agree to use reliable methods of during the trial period and until follow-up for the last time.

    7.Absence of symptoms of central nervous system(CNS) leukemia.

Exclusion criteria

Exclusion Criteria:

  1. Patients who have been treated with chemotherapy or radiotherapy within 2 weeks before blood collection.
  2. Patients have , which needs treatment with agents,or patients with diseases.
  3. Patient who have been treated with systemic medication within two weeks of blood collection(Except for the recent or current use of inhaled steroids).
  4. Patient who have been treated with stimulation of bone marrow hematopoietic cells generated drugs(Such as Recombinant Human Granulocyte Colony-stimulating Factor Injection) within 2 weeks before the blood collection period to use .
  5. The number of T cells in peripheral blood is lower than 2×10\^8/L.
  6. Previously treatment with any gene therapy products.
  7. History of epilepsy or other CNS disease.
  8. (NYHA) grade≥Ⅲ.
  9. Creatinine> 1.5×normal value,(ALT) /Aspartate aminotransferase(AST)>3×normal value, >2×normal value.
  10. Degree of myeloproliferation: Ⅳ-V
  11. Active , or infection and cytomegalovirus infection ,Epstein-Barr virus infection or any other uncontrolled active infection.
  12. Pregnancy or breast-feeding women.
  13. Any uncontrolled medical disorders that the researchers considered are not suitable to participate the clinical trial.
  14. Any situation that would increase dangerousness of subjects or disturb the outcome of the clinical study according to the researcher's evaluation.
Terms in these criteria, in plain language(17)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

GVHD (graft-versus-host disease)

After a transplant from a donor, the donor’s immune cells attack the recipient’s body, often the skin, gut or liver.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
20 participants (estimated)

Study arms

  • Experimental
    IM19 CART

    All patients will be treated with fludarabine and cyclophosphamide for 3 days,then,CAR-T cells expressing CD19 CAR will be infused 24-96 hours later.

    Biological: IM19 CAR-T · Drug: Fludarabine · Drug: Cyclophosphamide

Interventions

  • BiologicalIM19 CAR-T

    All patients will be treated with fludarabine and cyclophosphamide for 3 days. Two days later, Cells Expressing an Anti-CD19 Chimeric Antigen Receptor will be infused.

    Also known as: IM19

  • Two days before cell infusion,all patients will be treated with fludarabine for 3 days

    Also known as: F

  • Two days before cell infusion,all patients will be treated with cyclophosphamide for 3 days

    Also known as: C

06

What researchers measure

Primary outcomes

  1. Occurrence of study related adverse events

    defined as \>= Grade 3 signs/symptoms,laboratory toxicities,and clinical events that are possibly,likely,or definitely related to study treatment Adverse events assessed according to NCI-CTCAE v4.0 criteria 2.

    Time frame: 2 years

Secondary outcomes

  1. Overall response rate

    2. Overall response rate An objective response is defined as: (1) a morphologic complete response (CR) or (2) a complete response with incomplete recovery of counts (CRi) (based on NCCN guidelines (National Comprehensive Cancer Network (NCCN), 2014) or (3) a negative minimal residual disease assessed by flow cytometry

    Time frame: 2 years

07

Study locations

1 of 1 sites recruiting
  • Peking University Third Hospital
    Beijing, Beijing, China
    Recruiting
08

References and documents

Publications

  • Bao F, Wan W, He T, Qi F, Liu G, Hu K, Lu XA, Yang P, Dong F, Wang J, Jing H. Autologous CD19-directed chimeric antigen receptor-T cell is an effective and safe treatment to refractory or relapsed diffuse large B-cell lymphoma. Cancer Gene Ther. 2019 Jul;26(7-8):248-255. doi: 10.1038/s41417-018-0073-7. Epub 2019 Jan 9. PubMed 30622321 ↗
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2017 (actual). Primary completion is estimated for Oct 2020, 37 months after the start.

Of 95 industry-sponsored phase 1 interventional studies under Hematologic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 78. This study's planned 37 months is below that.

Counting every sponsor, half of 159 studies reached it within 51 months; a quarter within 28 and three quarters within 78.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2017
First posted
Nov 17, 2017
StartActual
Aug 21, 2017
Primary completionEst.
Oct 1, 2020
CompletionEst.
Dec 1, 2020
Last update
Nov 17, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Nov 17, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03344705
Responsible party
Sponsor
First posted
Nov 17, 2017
Start date
Aug 21, 2017
Primary completion
Oct 1, 2020 (estimated)
Completion
Dec 1, 2020 (estimated)
Last update
Nov 17, 2017

Study contacts

Xin-an Lu, Dr
Contact
luxinan@immunochina.com
86-189-1157-6946
Hongmei Jing, MD
principal investigator · Peking University Third Hospital

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Nov 2017. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: IM19

Start the discussion